332 related articles for article (PubMed ID: 25897811)
21. Prime-boost immunization strategies against Chikungunya virus.
Hallengärd D; Lum FM; Kümmerer BM; Lulla A; Lulla V; García-Arriaza J; Fazakerley JK; Roques P; Le Grand R; Merits A; Ng LF; Esteban M; Liljeström P
J Virol; 2014 Nov; 88(22):13333-43. PubMed ID: 25210177
[TBL] [Abstract][Full Text] [Related]
22. DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice.
Tretyakova I; Hearn J; Wang E; Weaver S; Pushko P
J Infect Dis; 2014 Jun; 209(12):1882-90. PubMed ID: 24585894
[TBL] [Abstract][Full Text] [Related]
23. Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice.
Hallengärd D; Kakoulidou M; Lulla A; Kümmerer BM; Johansson DX; Mutso M; Lulla V; Fazakerley JK; Roques P; Le Grand R; Merits A; Liljeström P
J Virol; 2014 Mar; 88(5):2858-66. PubMed ID: 24371047
[TBL] [Abstract][Full Text] [Related]
24. Recent development in the strategies projected for chikungunya vaccine in humans.
Goyal M; Chauhan A; Goyal V; Jaiswal N; Singh S; Singh M
Drug Des Devel Ther; 2018; 12():4195-4206. PubMed ID: 30573950
[TBL] [Abstract][Full Text] [Related]
25. Chikungunya virus: recent advances in epidemiology, host pathogen interaction and vaccine strategies.
Deeba F; Islam A; Kazim SN; Naqvi IH; Broor S; Ahmed A; Parveen S
Pathog Dis; 2016 Apr; 74(3):. PubMed ID: 26657109
[TBL] [Abstract][Full Text] [Related]
26. Prophylactic strategies to control chikungunya virus infection.
Hucke FIL; Bestehorn-Willmann M; Bugert JJ
Virus Genes; 2021 Apr; 57(2):133-150. PubMed ID: 33590406
[TBL] [Abstract][Full Text] [Related]
27. Expression and Characterization of Yeast Derived Chikungunya Virus Like Particles (CHIK-VLPs) and Its Evaluation as a Potential Vaccine Candidate.
Saraswat S; Athmaram TN; Parida M; Agarwal A; Saha A; Dash PK
PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004782. PubMed ID: 27399001
[TBL] [Abstract][Full Text] [Related]
28. Antiviral Strategies Against Chikungunya Virus.
Abdelnabi R; Neyts J; Delang L
Methods Mol Biol; 2016; 1426():243-53. PubMed ID: 27233277
[TBL] [Abstract][Full Text] [Related]
29. Antiviral therapeutics for chikungunya virus.
Ghildiyal R; Gabrani R
Expert Opin Ther Pat; 2020 Jun; 30(6):467-480. PubMed ID: 32249636
[No Abstract] [Full Text] [Related]
30. A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes.
Goo L; Dowd KA; Lin TY; Mascola JR; Graham BS; Ledgerwood JE; Pierson TC
J Infect Dis; 2016 Nov; 214(10):1487-1491. PubMed ID: 27655868
[TBL] [Abstract][Full Text] [Related]
31. Chikungunya virus infections: time to act, time to treat.
Abdelnabi R; Neyts J; Delang L
Curr Opin Virol; 2017 Jun; 24():25-30. PubMed ID: 28414993
[TBL] [Abstract][Full Text] [Related]
32. Mutating chikungunya virus non-structural protein produces potent live-attenuated vaccine candidate.
Chan YH; Teo TH; Utt A; Tan JJ; Amrun SN; Abu Bakar F; Yee WX; Becht E; Lee CY; Lee B; Rajarethinam R; Newell E; Merits A; Carissimo G; Lum FM; Ng LF
EMBO Mol Med; 2019 Jun; 11(6):. PubMed ID: 31015278
[TBL] [Abstract][Full Text] [Related]
33. Antibody-based therapeutic interventions: possible strategy to counter chikungunya viral infection.
Kumar R; Shrivastava T; Samal S; Ahmed S; Parray HA
Appl Microbiol Biotechnol; 2020 Apr; 104(8):3209-3228. PubMed ID: 32076776
[TBL] [Abstract][Full Text] [Related]
34. Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits.
Metz SW; Martina BE; van den Doel P; Geertsema C; Osterhaus AD; Vlak JM; Pijlman GP
Vaccine; 2013 Dec; 31(51):6092-6. PubMed ID: 24099875
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity and Efficacy of a Measles Virus-Vectored Chikungunya Vaccine in Nonhuman Primates.
Rossi SL; Comer JE; Wang E; Azar SR; Lawrence WS; Plante JA; Ramsauer K; Schrauf S; Weaver SC
J Infect Dis; 2019 Jul; 220(5):735-742. PubMed ID: 31053842
[TBL] [Abstract][Full Text] [Related]
36. Effective cutaneous vaccination using an inactivated chikungunya virus vaccine delivered by Foroderm.
Rudd PA; Raphael AP; Yamada M; Nufer KL; Gardner J; Le TT; Prow NA; Dang N; Schroder WA; Prow TW; Suhrbier A
Vaccine; 2015 Sep; 33(39):5172-80. PubMed ID: 26296498
[TBL] [Abstract][Full Text] [Related]
37. Live-attenuated RNA hybrid vaccine technology provides single-dose protection against Chikungunya virus.
Voigt EA; Fuerte-Stone J; Granger B; Archer J; Van Hoeven N
Mol Ther; 2021 Sep; 29(9):2782-2793. PubMed ID: 34058388
[TBL] [Abstract][Full Text] [Related]
38. A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial.
Folegatti PM; Harrison K; Preciado-Llanes L; Lopez FR; Bittaye M; Kim YC; Flaxman A; Bellamy D; Makinson R; Sheridan J; Azar SR; Campos RK; Tilley M; Tran N; Jenkin D; Poulton I; Lawrie A; Roberts R; Berrie E; Rossi SL; Hill A; Ewer KJ; Reyes-Sandoval A
Nat Commun; 2021 Jul; 12(1):4636. PubMed ID: 34330906
[TBL] [Abstract][Full Text] [Related]
39. Loss of TLR3 aggravates CHIKV replication and pathology due to an altered virus-specific neutralizing antibody response.
Her Z; Teng TS; Tan JJ; Teo TH; Kam YW; Lum FM; Lee WW; Gabriel C; Melchiotti R; Andiappan AK; Lulla V; Lulla A; Win MK; Chow A; Biswas SK; Leo YS; Lecuit M; Merits A; Rénia L; Ng LF
EMBO Mol Med; 2015 Jan; 7(1):24-41. PubMed ID: 25452586
[TBL] [Abstract][Full Text] [Related]
40. Extended Preclinical Safety, Efficacy and Stability Testing of a Live-attenuated Chikungunya Vaccine Candidate.
Plante KS; Rossi SL; Bergren NA; Seymour RL; Weaver SC
PLoS Negl Trop Dis; 2015; 9(9):e0004007. PubMed ID: 26340754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
